Hyperhidrosis Treatment Market Trends

Global Hyperhidrosis Treatment Market Overview

Hyperhidrosis Treatment Market Size was valued at USD 0.9 Billion in 2022. The hyperhidrosis treatment market industry is projected to grow from USD 0.95 Billion in 2023 to USD 1.50 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.90% during the forecast period (2023 - 2032). The prevalence of the disease, particularly axillary hyperhidrosis in industrialized nations, is one of the major market drivers driving the market's rise for hyperhidrosis treatments. In addition, the market expansion is predicted to be considerably fueled by expanding product launches and product approvals around the globe as well as rising demand for healthcare services. 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

A press release from Candesant Biomedical stated that the FDA has approved a de novo request for Brella, a non-invasive treatment option for primary axillary hyperhidrosis employing focused alkali thermolysis technology. Candesant’s targeted alkali thermolysis (TAT) technology is used to develop Brella, which reduces excessive underarm sweating in adults with primary axillary hyperhidrosis. The doctor has shown that this patch can be used only once; it is disposable and does not contain aluminum. After being put on during a visit to the office, it lasts about 3-4 months. The American Academy of Dermatology Annual Meeting Saharan is a randomized, double-blind, and sham-controlled trial. This gave rise to the approval.

Botanix Pharmaceuticals Limited had its name added to the ASX All Ordinaries Index in April 2024 following its amazing performance and investor interest over the period of one year. Consequently, Botanix has generated higher stock prices due to an expected FDA approval for Sofdra™, a first-of-its-kind treatment for underarm sweating that is already preparing for product launch. Its commercial launch after anticipated ok and subsequent market entry into late June next year will enable Botanix to consolidate its position as a clinical dermatology company.

According to a public disclosure, Lily has decided to purchase Dermira in an all-cash deal at an agreed upon price of $18.75 per share meaning it will pay around $1.1 billion for the company through this definitive agreement. As a biopharmaceutical company that specializes in developing therapies for chronic skin diseases, Dermira is positioned as a takeover target by Lilly. The acquisition thus widens the immunology portfolio of Lilly with the inclusion of Lebrikizumab; a unique investigational monoclonal antibody designed to bind IL-13 with high affinity that’s still going through Phase 3 clinical trials in adolescents and adult patients aged 12 years and older with moderate-to-severe atopic dermatitis.

Hyperhidrosis Treatment Market Trends

• Increase in the prevalence of secondary hyperhidrosis is driving the market growth

When an underlying medical condition causes excessive sweating, the disorder is referred to as secondary hyperhidrosis. The less common condition is more likely to cause excessive body sweat. The market for secondary hyperhidrosis therapy is growing as secondary hyperhidrosis prevalence rises. The 2020 International Hyperhidrosis Society estimates that 365 million people, or around 5% of the world's population, experience secondary hyperhidrosis and excessive sweating. In contrast to primary hyperhidrosis, which commonly starts in childhood or adolescence, excessive sweating typically starts in adulthood. Therefore, chronic illnesses are more prevalent among adults. Due to the rapid rise of the adult population, secondary hyperhidrosis is becoming more common. Additionally, the journal predicts that by 2030, there will be 643 million people living with diabetes worldwide, and by 2045, there will be 783 million. These numbers suggest that as the prevalence of diabetes mellitus increases, so will the incidence of secondary hyperhidrosis. As a result, it is projected that the factors above would enhance demand for hyperhidrosis therapies, aiding the market's overall growth.

Botulinum toxin is a medication used to control medical and cosmetic issues. The therapeutic applications include cervical dystonia, detrusor hyperactivity, chronic migraine, and spastic disorders. It is a member of the class of medications known as neurotoxins. The nerves that regulate the sweat glands in the underarm, foot, and palm regions are momentarily blocked by injections of Botox, a protein produced by the Clostridium botulinum bacteria. Results are noticeable after five days, but more therapy is needed after four to six months. This time frame is sufficient for curing hyperhidrosis and is therefore anticipated to propel market revenue growth. The market for hyperhidrosis treatment is growing in revenue due to an increase in public awareness of the importance of recognizing and treating disorders like hyperhidrosis.

Using a direct electric current to transmit an ionized material through the skin, tap water iontophoresis is another hyperhidrosis treatment that is becoming increasingly well-liked by patients. Several clinical studies showed considerable improvements in patients with plantar and palmar hyperhidrosis. These beneficial outcomes helped patients live better lives and significantly reduced the sweat they produced. Thus, driving the hyperhidrosis treatment market revenue.

Hyperhidrosis Treatment Market Segment Insights

Hyperhidrosis Treatment Treatment Insights

The hyperhidrosis treatment market segmentation, based on treatment includes Botulinum Toxin Injections, Topical Treatment, Surgical Treatment, Oral Medication and Microwave Therapy. The topical treatment segment dominated the market. Topical treatments for hyperhidrosis include aluminum chloride, astringent chemicals, and local anesthetics. The topical anticholinergic wipes have FDA approval. For cosmetic purposes, the general populous of industrialized countries use over-the-counter antiperspirants to control underarm sweating and odor. But more active treatment is required for those with moderate to severe hyperhidrosis. Compared to people with psoriasis or atopic dermatitis, people with hyperhidrosis have a substantially lower quality of life.

Hyperhidrosis Treatment Type Insights

The hyperhidrosis treatment market segmentation, based on type, includes Primary Hyperhidrosis and Secondary Generalized Hyperhidrosis. The primary hyperhidrosis category generated the most income. Primary hyperhidrosis, a condition that produces excessive sweating in those areas, affects several body parts, including the underarms, feet, and palms. Primary hyperhidrosis is excessive sweating in the axillae, palms, soles, or craniofacial region that is bilaterally symmetric and unrelated to other underlying illnesses. Primarily inherited, primary hyperhidrosis normally first appears in childhood and worsens with puberty, especially in women. People affected could react more strongly to stimuli that can make them sweat, such as stress, anxiety, exercise, pain, coffee, and nicotine.

Figure 1: Hyperhidrosis Treatment Market, by Type, 2022 & 2032 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Hyperhidrosis Treatment End-User Insights

The hyperhidrosis treatment market segmentation, based on end-user, includes Dermatology Clinics, Ambulatory Surgery Centers and Payers/Patients. The dermatology clinics category generated the most income. This market will be driven by the rising demand for minimally invasive procedures, non-invasive surgery, and medication therapies in the upcoming years. Additionally, due to their high price range and quality service provided at the end, many patients choose to visit a clinic rather than have surgery. This helps produce money in return.

Hyperhidrosis Treatment Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American hyperhidrosis treatment market area will dominate this market. The market is driven by the nation's large market players, technological advancements, the rising incidence of primary hyperhidrosis, cancer, cardiovascular disorders that exacerbate secondary hyperhidrosis, and the rising prevalence of primary hyperhidrosis. Due to the high frequency of primary and secondary hyperhidrosis, treatment adoption will increase nationally.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: HYPERHIDROSIS TREATMENT MARKET SHARE BY REGION 2022 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe hyperhidrosis treatment market accounts for the second-largest market share. Several international pharmaceutical and medical device companies with a sizable presence in Germany are working on hyperhidrosis remedies. Additionally, it is anticipated that the expansion of hyperhidrosis-related research and development and the rise in primary and secondary hyperhidrosis prevalence will fuel market growth throughout the projected decade. Further, the German hyperhidrosis treatment market held the largest market share, and the UK hyperhidrosis treatment market was the fastest growing market in the European region.

The Asia-Pacific Hyperhidrosis treatment Market is expected to grow at the fastest CAGR from 2023 to 2032 because of enhanced technology developments that produce safe and side-effect-free treatment alternatives and support from public and commercial entities. Similarly to this, it is anticipated that greater investment by biotechnology and pharmaceutical businesses will raise industry demand. Moreover, China’s hyperhidrosis treatment market held the largest market share, and the Indian hyperhidrosis treatment market was the fastest growing market in the Asia-Pacific region.

Hyperhidrosis Treatment Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the hyperhidrosis treatment market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, hyperhidrosis treatment industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the hyperhidrosis treatment industry to benefit clients and increase the market sector. In recent years, the hyperhidrosis treatment industry has offered some of the most significant advantages to market. Major players in the hyperhidrosis treatment market attempting to increase market demand by investing in research and development operations include Brickell Biotech Inc. (US), Allergan PLC (Ireland), Cynosure (US), Dermira Inc. (US), Dermadry Laboratories inc. (Canada), GlaxoSmithKline PLC (UK), Sesderma (Spain), Miramar Labs Inc. (US) and Ulthera Inc. (US).

A division of AbbVie Inc., Allergan Ltd. (Allergan) is a specialty pharmaceutical company that creates and markets biosimilar and over-the-counter (OTC) medications and branded prescription drugs. It provides products for the central nervous system, dermatology, eye care, women's health, urology, medical aesthetics, and anti-infective therapeutic categories. The business sells its goods to retailers, distributors, national chains of grocery and drug stores, drug wholesalers, mail-order businesses, healthcare facilities including hospitals and clinics, government organizations, and managed healthcare providers like HMOs and other organizations.

The major producer of iontophoresis devices for treating hyperhidrosis, a disease that causes excessive sweating and affects one in twenty persons globally, is Dermadry. It offers three specialized treatments for the hands, feet, and underarms—the three areas most frequently impacted by hyperhidrosis. The Dermadry Hands & Feet, Dermadry Underarms, and the all-in-one Dermadry Total are among the Canadian-made iontophoresis devices offered by this company.

Key Companies in the hyperhidrosis treatment market include

• 
  

  Brickell Biotech Inc. (US)

  
  


• 
  

  Allergan PLC (Ireland)

  
  


• 
  

  Cynosure (US)

  
  


• 
  

  Dermira Inc. (US)

  
  


• 
  

  Dermadry Laboratories inc. (Canada)

  
  


• 
  

  GlaxoSmithKline PLC (UK)

  
  


• 
  

  Sesderma (Spain)

  
  


• 
  

  Miramar Labs Inc. (US)

  
  


• 
  

  Ulthera Inc. (US)

  
  

Hyperhidrosis Treatment Industry Developments

October 2022:Candesant Biomedical started the "SweatTech Initiative" to enlighten people about the serious effects of hyperhidrosis, show how treatments have changed over time, and highlight the continued need for more advanced therapies.

July 2022:More than 30 abstracts were presented during the TOXINS 2022 Conference in July in New Orleans, according to AbbVie and Allergan Aesthetics. Seven podium presentations were among them. Onabotulinumtoxin (BOTOX and BOTOX Cosmetic) would be highlighted across authorized and investigational indications by clinical studies, preclinical research, health economics, and actual usage data.

May 2022:Rapifort Wipes were introduced by Meruho in Japan to treat primary axillary hyperhidrosis. It was the nation's first prescription wipe preparation.

Hyperhidrosis Treatment Market Segmentation

Hyperhidrosis Treatment Treatment Outlook (USD Billion, 2018-2032)

• 
  

  Botulinum Toxin Injections

  
  


• 
  

  Topical Treatment

  
  


• 
  

  Surgical Treatment

  
  


• 
  

  Oral Medication

  
  


• 
  

  Microwave Therapy

  
  

Hyperhidrosis Treatment Type Outlook (USD Billion, 2018-2032)

• 
  

  Primary Hyperhidrosis

  
  


• 
  

  Secondary Generalized Hyperhidrosis

  
  

Hyperhidrosis Treatment End-User Outlook (USD Billion, 2018-2032)

• 
  

  Dermatology Clinics

  
  


• 
  

  Ambulatory Surgery Centers

  
  


• 
  

  Payers/Patients

  
  

Hyperhidrosis Treatment Regional Outlook (USD Billion, 2018-2032)

• 
  

  North America

  
  

• 
  

  US

  
  


• 
  

  Canada

  
  

• 
  

  Europe

  
  

• 
  

  Germany

  
  


• 
  

  France

  
  


• 
  

  UK

  
  


• 
  

  Italy

  
  


• 
  

  Spain

  
  


• 
  

  Rest of Europe

  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America